Price
No data yet.
Social Signal Score
Revenue
$2.11MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Wayne Geoffrey Paterson
- Sector
- Healthcare
- Industry
- Medical - Devices
- Beta
- 0.75
- Country
- AU
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -3.29
Financials
Revenue
$2.11M-37.5%Net Income
$-66.62MEBITDA
$-66.95MFree Cash Flow
$0.00EPS (diluted)
$-3.02Shares Outstanding (diluted)
22.05M+29464.8%Operating Expenses
$69.10MCash & Debt
$113.84MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2024 | $4.37M | $-123.26M | $-6.09 |
| 2023 | $4.01M | $-67.33M | $-4.31 |
| 2022 | $4.59M | $-44.34M | $-3.32 |
| 2021 | $7.79M | $-22.91M | $-3.09 |
| 2020 | $7.08M | $-15.27M | $-2.58 |
| 2019 | $17.08M | $-5.82M | $-0.99 |
| 2018 | $25.60M | $-24.22M | $-7.93 |
| 2017 | $22.61M | $-17.26M | $-6.78 |
| 2016 | $22.32M | $-12.31M | $-4.90 |
| 2015 | $14.15M | $-24.01M | $-12.58 |
| 2014 | $10.13M | $-25.25M | $-16.48 |
| 2013 | $7.90M | $-6.62M | $-5.44 |
| 2012 | $7.40M | $-1.89M | $-2.05 |
| 2011 | $6.44M | $-10.00M | $-14.84 |
Valuation
AMEUFhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
30-40.00%Social Signal Score
Mentions (8)
- Newsglobenewswire.com·17h ago·Negative
Anteris' DurAVR THV Demonstrates 1% Heart Failure Hospitalization, Single-Digit Gradients and No Valve-Related Deaths at 1 Year in Patients with Small Aortic Annuli Anteris' DurAVR THV Shows 1% Heart Failure Hospitalization, Single-Digit Gradients and No Valve-Related Deaths at 1 Year in Patients with Small Annuli
View source ↗ - Newsglobenewswire.com·12d ago·Neutral
Anteris Technologies Announces Results for the Third Quarter of 2026 MINNEAPOLIS and BRISBANE, Australia, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR), a global healthcare company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today reported financial results for the quarter ended September 30, 2026, and provided a corporate update. Q3 2026 Highligh
View source ↗ - Newsglobenewswire.com·21d ago·Positive
Anteris Reports Medium-Size DurAVR THV Outcomes from the EMBARK Study at TCT 2026 MINNEAPOLIS and BRISBANE, Australia, Nov. 01, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global healthcare company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced 30-day clinical and hemodynamic outcomes for the Medium-size DurAVR® Transcatheter Heart Valve (
View source ↗ - Newsglobenewswire.com·26d ago·Positive
Anteris Announces Upcoming Data Release for Medium-Size DurAVR THV from EMBARK Study at TCT 2026 MINNEAPOLIS and BRISBANE, Australia, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) today announced that Azeem Latib, MD, will present the first 30-day clinical and hemodynamic outcomes for its medium-size DurAVR® Transcatheter Heart Valve (THV) at TCT® 2026 – The 38th Annual Transcatheter Cardiovascular Therapeutics Conference
View source ↗ - Newsproactiveinvestors.com·34d ago·Negative
Anteris Technologies secures German clearance to expand PARADIGM heart valve trial Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) has secured full German regulatory clearance for its pivotal PARADIGM trial, allowing the company to begin recruiting patients in Europe's largest transcatheter aortic valve replacement market. Germany's Federal Institute for Drugs and Medical Devices has cleared the DurAVR® Transcatheter Heart Valve study for patients with severe calcific aortic stenosis, opening
View source ↗ - Newsglobenewswire.com·34d ago·Negative
Anteris Advances Global PARADIGM Trial Expansion with German Regulatory Clearance MINNEAPOLIS and BRISBANE, Australia, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) announced today that it has received full regulatory clearance from the German Federal Institute for Drugs and Medical Devices (BfArM) for the DurAVR® Transcatheter Heart Valve (THV) global pivotal trial for patients with severe calcific aortic stenosis (the “
View source ↗ - Newsglobenewswire.com·83d ago·Neutral
Anteris to Present at September Healthcare Investor Conferences MINNEAPOLIS and BRISBANE, Australia, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global healthcare company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, is pleased to advise that Vice Chairman and Chief Executive Officer, Wayne Paterson, will be presenting at the Cantor Global Healt
View source ↗ - Newsglobenewswire.com·103d ago·Negative
Anteris Technologies Announces Results for the Second Quarter of 2026 MINNEAPOLIS and BRISBANE, Australia, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global healthcare company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today reported financial results for the quarter ended June 30, 2026, and provided a corporate update. Q2 2026 Highlights Se
View source ↗
Earnings
Typical surprise -83.4% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Oct 31$-1.83 vs $-1.00miss
Estimates and results for AMEUF via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
No disclosed congressional trades in AMEUF.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
